Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes-Reference-Cited by-同舟云学术

Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes

Published:2023-01 Issue: Volume:353 Page:254-269
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Hirsch Shira,Hinden Liad,Naim Meital Ben-David,Baraghithy Saja,Permyakova Anna,Azar Shahar,Nasser Taher,Portnoy Emma,Agbaria Majd,Nemirovski Alina,Golomb Gershon,Tam Joseph

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference105 articles.

1. Nonalcoholic fatty liver disease;Angulo;Rev. Gastroenterol. Mex.,2005

2. Non-alcoholic fatty liver disease: the mist gradually clears;de Alwis;J. Hepatol.,2008

3. Non-alcoholic steatohepatitis in type 2 diabetes mellitus;Gupte;J. Gastroenterol. Hepatol.,2004

4. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment;Smith;Nat. Rev. Endocrinol.,2011

5. Cannabinoid receptor signaling;Howlett;Handb. Exp. Pharmacol.,2005

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications;Journal of Liposome Research;2024-07-10

2. Gut Microbiota-Mediated Alterations of Hippocampal CB1R Regulating the Diurnal Variation of Cognitive Impairment Induced by Hepatic Ischemia–Reperfusion Injury in Mice;Neurochemical Research;2024-06-02

3. Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders;Journal of Medicinal Chemistry;2023-08-23

4. A Comprehensive Review on Prospects of Polymeric Nanoparticles for Treatment of Diabetes Mellitus: Receptors-Ligands, In vitro & In vivo Studies;Recent Patents on Nanotechnology;2023-08-03

5. Targeted delivery of nutraceuticals derived from food for the treatment of obesity and its related complications;Food Chemistry;2023-08